Antiplatelet

One drawback of thrombolytic therapy is a high incidence of reocclusion. In a report using a canine model, inclusion of heparin [9005-49-6] (anticoagulant therapy) in the treatment prevented this side effect (158). The combination of aspirin [50-78-2] (antiplatelet therapy) and streptokinase (thrombolytic therapy) has also shown significant therapeutic advantages (78). Although additional work is needed to estabUsh the thrombolytic advantage of various combinations, preliminary results in this area indicate promise in terms of increased efficacy and reduced side effects. [Pg.311]

Two general methods of improving polymer hemocompatibility are known (1) grafting of hydrophilic chains, and (2) the chemical attachment of an antiplatelet agent. In this respect, many hydrophilic and other monomers are grafted on solid polyurethane surfaces such as... [Pg.255]

Polymers with an antiplatelet agent of 5-(6-carboxyl-hexyl) l-(3-cyclohexyl-3-hydroxyropyl) hydantoin as an end group were synthesized by esterifying the hydantoin molecule with a haloalcohol, such as CCI3CH2OH or BrCH2CH20H, and using the product as coinitiator with... [Pg.256]

Mn2(CO)io in a simple photoinitiated free radical polymerization. The antiplatelet activity of these polymers were compared with that of poly(ether-Wrethane) carrying the hydantoin residues in side chains. [Pg.256]

Mousa SA (1999) Antiplatelet therapies from Aspirin to GPIIb/IIIa receptor antagonists and beyond. Drag Discov Today 4(12) 552-561... [Pg.146]

Platelets play a central role in primary hemostasis. They are also important in pathological processes leading to thrombosis. Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms. They are used for the prevention and treatment of thrombotic processes, especially in the arterial vascular system. [Pg.167]

Most antiplatelet dtugs only partially inhibit platelet activation. In contrast, blockers of GPIIb/llla interfere at the end of the pathway common to platelet aggregation. They prevent fibrinogen and vWf from... [Pg.168]

Due to the pivotal role of platelets in thrombus formation, especially in the arterial system, inhibition of platelet function has become a central pharmacological approach. Antiplatelet drugs are given in order to prevent and treat thromboembolic diseases such as coronary heart disease, peripheral and cerebrovascular disease. They have also revolutionized the procedures of invasive coronary interventions as they reduce the risk of restenosis and thrombosis. [Pg.170]

Jackson SP, Schoenwaelder SM (2003) Antiplatelet therapy in search of the magic bullet . Nat Rev Drag Discov 2 775-789... [Pg.171]

Antiplatetelet Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 71-86... [Pg.171]

Bhatt DL, Topol EJ (2003) Scientific and Therapeutic Advances in Antiplatelet Therapy. Nat Rev Drag Discov 2 15-28... [Pg.171]

Pharmacological management of risk factors through antihypertensive, antihyperlipidemic, and antidiabetic therapy coupled with antiplatelet drugs comprise the... [Pg.227]

HMG-CoA-Reductase-Inhibitors Peroxisome Proliferator-Activated Recqrtors (PPARs) ACE Inhibitors Antiplatelet Drugs... [Pg.229]

Non-steroidal Anti-inflammatoty Dtugs Antiplatelet Dtugs... [Pg.395]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...